These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18257772)

  • 1. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A; Carey D; Mallon PW; Wand H; Law M; Cooper DA; Carr A; ;
    HIV Med; 2008 Feb; 9(2):101-10. PubMed ID: 18257772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
    Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
    Nguyen A; Calmy A; Schiffer V; Bernasconi E; Battegay M; Opravil M; Evison JM; Tarr PE; Schmid P; Perneger T; Hirschel B;
    HIV Med; 2008 Mar; 9(3):142-50. PubMed ID: 18218001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
    Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study.
    Wunder DM; Fux CA; Bersinger NA; Mueller NJ; Hirschel B; Cavassini M; Elzi L; Schmid P; Bernasconi E; Mueller B; Furrer H;
    HIV Med; 2008 Jul; 9(6):427-32. PubMed ID: 18459947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
    He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
    Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
    Egaña-Gorroño L; Martínez E; Pérez I; Escribà T; Domingo P; Gatell JM; Arnedo M
    J Antimicrob Chemother; 2014 Nov; 69(11):3076-84. PubMed ID: 25185137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
    Hartman K; Verweel G; de Groot R; Hartwig NG
    Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults.
    Law M; Puls R; Cheng AK; Cooper DA; Carr A
    Antivir Ther; 2006; 11(2):179-86. PubMed ID: 16640099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
    Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
    Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.